Erica Rakowsky

Medicine & Life Sciences

1. Radiotherapy 100%
2. Breast Neoplasms 91%
3. Survival 90%
4. Drug Therapy 88%
5. Kaposi's Sarcoma 68%
6. Neoplasms 67%
7. Israel 54%
8. Jews 45%
9. Second Primary Neoplasms 44%
10. Adjuvant Chemotherapy 44%
11. Non-Hodgkin's Lymphoma 42%
12. Recurrence 42%
13. Lymphoma 42%
14. Carcinoma 38%
15. Tumor Biomarkers 38%
16. Induction Chemotherapy 36%
17. Therapeutics 36%
18. Estrogen Receptors 36%
19. Laryngeal Neoplasms 35%
20. Disease-Free Survival 35%
21. tissue polypeptide specific antigen 34%
22. Neoplasm Metastasis 34%
23. Melanoma 33%
24. Hydroxymethylbilane Synthase 31%
25. Colorectal Neoplasms 30%
26. Male Breast Neoplasms 27%
27. Lymph Nodes 27%
28. Familial primary gastric lymphoma 27%
29. Leucovorin 27%
30. Clinical Studies 27%
31. Multivariate Analysis 26%
32. Merkel Cell Carcinoma 26%
33. Extranodal Extension 26%
34. Tongue Neoplasms 26%
35. Leukoencephalopathies 25%
36. Liposarcoma 25%
37. Progesterone Receptors 24%
38. Heart Neoplasms 23%
39. Methotrexate 23%
40. Induced Hyperthermia 23%
41. Leiomyosarcoma 23%
42. Histocompatibility Antigens Class I 23%
43. Biological Therapy 23%
44. Nasopharynx 23%
45. Viral Antigens 22%
46. Microwaves 22%
47. Capsid 22%
48. Nasopharyngeal Carcinoma 22%
49. Survival Rate 21%
50. Hypercalcemia 21%